Kiniksa Pharmaceuticals Ltd. Class A ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Kiniksa Pharmaceuticals Ltd. Class A zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Kiniksa Pharmaceuticals Ltd. Class A zu Deinem Portfolio hinzuzufügen.
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).
Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially. Arcalyst's strong performance has driven a $10 million increase in the full-year net sales guidance range. Kiniksa plans to develop abiprubart for the treatment of Sjogren's syndrome, with a large phase 2b trial expected to start in the second half of the year.
Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA ) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior Vice President & Chief Commercial Officer John Paolini - Senior Vice President & Chief Medical Officer Mark Ragosa - Senior Vice President & Chief Financial Offi...
– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abiprubart Phase 2b trial in Sjögren's Disease planned to initiate in 2H 2024 – – Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast schedule...
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution.
– Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 – – Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity – – Abiprubart development in Sjogren's Disease fully funded through Phase 3 – – Company expects to remain cash flow positive on an annual basis within current operating plan –
– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.